A new publication dated October 1, 2026 presents work titled "Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item." The paper appears in the journal Advances in Therapy.
The publication focuses on the development and psychometric evaluation of a measurement tool for hunger severity in individuals with rare MC4R pathway diseases. Setmelanotide is an approved therapy associated with this disease area, and this type of research often relates to the broader clinical and measurement context surrounding such conditions.
This entry reflects the existence and bibliographic details of the publication as listed. No specific findings, results, or conclusions from the study are included here, as that information was not provided in the available data. The listing confirms the title, journal, and publication date.
Readers interested in the measurement methodology or its intended use should consult the full publication directly through the journal. For additional background on setmelanotide, including its regulatory status and general information, readers can refer to the compound overview.